WHAT IS CLAIMED:

1. An oligomeric compound, or a salt thereof, comprising a modified oligonucleotide consisting of 16 linked nucleobases and having a nucleobase sequence consisting of the nucleobase sequence of SEQ ID NO: 2021, wherein the modified oligonucleotide comprises:


a gap segment consisting of nine linked deoxynucleosides;

a 5’ wing segment consisting of two linked nucleosides; and

a 3’ wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment; wherein each nucleoside of the 5’ wing segment comprises a cEt nucleoside; wherein the 3’ wing segment comprises a 2’-O-methoxyethyl nucleoside, a 2’-O-methoxyethyl nucleoside, a 2’-O-methoxyethyl nucleoside, a cEt nucleoside, and a cEt nucleoside in the 5’ to 3’ direction; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

2. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2021), or a salt thereof.

3. The oligomeric compound of claim 1, which is the sodium salt or the potassium salt.


4. The modified oligonucleotide of claim 2, which is the sodium salt or the potassium salt.

5. A modified oligonucleotide, wherein the anion form of the modified oligonucleotide has the following chemical structure:



(SEQ ID NO: 2021).

6. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2021).

7. A pharmaceutical composition comprising the oligomeric compound of claim 1 or claim 3, or the modified oligonucleotide of any one of claims 2, 4, 5, or 6, and a pharmaceutically acceptable carrier or diluent.

8. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable carrier comprises water or phosphate-buffered saline (PBS).

9. The pharmaceutical composition of claim 8, consisting essentially of the oligomeric compound or modified oligonucleotide and water or PBS.

10. The oligomeric compound of claim 1 or claim 3, the modified oligonucleotide of any one of claims 2, 4, 5, or 6, or the pharmaceutical composition of any one of claims 7-9 for use in treating or ameliorating a disease associated with IRF4 in an individual, wherein the oligomeric compound, the modified oligonucleotide, or the pharmaceutical composition is to be administered to the indvidual, thereby treating or ameliorating the disease associated with IRF4.

11. The oligomeric compound, modified oligonucleotide, or pharmaceutical composition for use of claim 10, wherein the disease associated with IRF4 is cancer.

12. The oligomeric compound, modified oligonucleotide, or pharmaceutical composition for use of claim 11 wherein the cancer is a blood cancer, myeloma, multiple myeloma (MM), B cell malignancy, lymphoma, B cell lymphoma, T cell lymphoma, or leukemia.

13. The oligomeric compound, modified oligonucleotide, or pharmaceutical composition for use of any one of claims 10-12, wherein the administration of the compound inhibits or reduces cancer cell proliferation, tumor growth, or metastasis.

14. Use of the oligomeric compound of claim 1 or claim 3, the modified oligonucleotide of any one of claims 2, 4, 5, or 6, or the pharmaceutical composition of any one of claims 7-9 in the manufacture of a medicament for the treatment of a disease associated with IRF4.

15. The use of claim 14, wherein the disease associated with IRF4 is a cancer.

16. The use of claim 15, wherein the cancer is a blood cancer, myeloma, multiple myeloma (MM), B cell malignancy, lymphoma, B cell lymphoma, T cell lymphoma, or leukemia.

17. The use of any one of claims 14-16, wherein treatment of a disease associated with IRF4 inhibits or reduces cancer cell proliferation, tumor growth, or metastasis.

18. The oligomeric compound of claim 1 or claim 3, the modified oligonucleotide of any one of claims 2, 4, 5, or 6, or the pharmaceutical composition of any one of claims 7-9, for use as a medicament.